WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 531517

CAS#: 942937-80-6 (NIH)

Description: AZD1386 is an orally available antagonist of the transient receptor potential channel TRPV1. Note: Structure of this product was from NIH/NCATS web page: and drugbank web page:

Chemical Structure

CAS# 942937-80-6 (NIH)

Theoretical Analysis

MedKoo Cat#: 531517
Name: AZD-1386
CAS#: 942937-80-6 (NIH)
Chemical Formula: C21H23F2N3O
Exact Mass: 371.18
Molecular Weight: 371.432
Elemental Analysis: C, 67.91; H, 6.24; F, 10.23; N, 11.31; O, 4.31

Price and Availability

Size Price Availability Quantity
5mg USD 350 Ready to ship
10mg USD 550 Ready to ship
25mg USD 950 Ready to ship
50mg USD 1650 Ready to ship
100mg USD 2950 Ready to ship
Bulk inquiry

Related CAS #: 946080-23-5   942937-80-6 (NIH),  

Synonym: AZD1386; AZD 1386; AZD-1386;

IUPAC/Chemical Name: 1H-Benzimidazole-1-acetamide, N-[(1S)-1-[4-(1,1-dimethylethyl)phenyl]ethyl]-6,7-difluoro-


InChi Code: InChI=1S/C21H23F2N3O/c1-13(14-5-7-15(8-6-14)21(2,3)4)25-18(27)11-26-12-24-17-10-9-16(22)19(23)20(17)26/h5-10,12-13H,11H2,1-4H3,(H,25,27)/t13-/m0/s1

SMILES Code: O=C(N[C@H](C1=CC=C(C(C)(C)C)C=C1)C)CN2C3=C(F)C(F)=CC=C3N=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target: AZD1386 is an orally available antagonist of the transient receptor potential channel TRPV1.
In vitro activity: TBD
In vivo activity: TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 371.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: TBD
In vitro protocol: TBD
In vivo protocol: TBD

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Quiding H, Jonzon B, Svensson O, Webster L, Reimfelt A, Karin A, Karlsten R, Segerdahl M. TRPV1 antagonistic analgesic effect: a randomized study of AZD1386 in pain after third molar extraction. Pain. 2013 Jun;154(6):808-12. doi: 10.1016/j.pain.2013.02.004. Epub 2013 Feb 19. PMID: 23541425.

2: Krarup AL, Ny L, Astrand M, Bajor A, Hvid-Jensen F, Hansen MB, Simrén M, Funch-Jensen P, Drewes AM. Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. Aliment Pharmacol Ther. 2011 May;33(10):1113-22. doi: 10.1111/j.1365-2036.2011.04629.x. Epub 2011 Mar 16. PMID: 21410733.

3: Krarup AL, Ny L, Gunnarsson J, Hvid-Jensen F, Zetterstrand S, Simrén M, Funch-Jensen P, Hansen MB, Drewes AM. Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain. Scand J Gastroenterol. 2013 Mar;48(3):274-84. doi: 10.3109/00365521.2012.758769. Epub 2013 Jan 16. PMID: 23320520.

4: Miller F, Björnsson M, Svensson O, Karlsten R. Experiences with an adaptive design for a dose-finding study in patients with osteoarthritis. Contemp Clin Trials. 2014 Mar;37(2):189-99. doi: 10.1016/j.cct.2013.12.007. Epub 2014 Jan 3. PMID: 24394343.

5: Vela MF. Medical treatments of GERD: the old and new. Gastroenterol Clin North Am. 2014 Mar;43(1):121-33. doi: 10.1016/j.gtc.2013.12.001. Epub 2013 Dec 31. PMID: 24503363.

6: Garami A, Shimansky YP, Rumbus Z, Vizin RCL, Farkas N, Hegyi J, Szakacs Z, Solymar M, Csenkey A, Chiche DA, Kapil R, Kyle DJ, Van Horn WD, Hegyi P, Romanovsky AA. Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: Insights from mathematical modeling and meta-analysis. Pharmacol Ther. 2020 Apr;208:107474. doi: 10.1016/j.pharmthera.2020.107474. Epub 2020 Jan 9. PMID: 31926897.

7: Kort ME, Kym PR. TRPV1 antagonists: clinical setbacks and prospects for future development. Prog Med Chem. 2012;51:57-70. doi: 10.1016/B978-0-12-396493-9.00002-9. PMID: 22520471.

8: Ängeby Möller K, Berge OG, Finn A, Stenfors C, Svensson CI. Using gait analysis to assess weight bearing in rats with Freund׳s complete adjuvant- induced monoarthritis to improve predictivity: Interfering with the cyclooxygenase and nerve growth factor pathways. Eur J Pharmacol. 2015 Jun 5;756:75-84. doi: 10.1016/j.ejphar.2015.02.050. Epub 2015 Mar 16. PMID: 25792342.

9: Parkinson J, Visser SA, Jarvis P, Pollard C, Valentin JP, Yates JW, Ewart L. Translational pharmacokinetic-pharmacodynamic modeling of QTc effects in dog and human. J Pharmacol Toxicol Methods. 2013 Nov-Dec;68(3):357-66. doi: 10.1016/j.vascn.2013.03.007. Epub 2013 Apr 6. PMID: 23567074.